N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic).
Phase:
PHASE1
Details
Lead Sponsor:
Vadim S Koshkin
Collaborator:
ImmunityBio, Inc.
Treatments:
ALT-803 enfortumab vedotin Magnetic Resonance Spectroscopy pembrolizumab Phantoms, Imaging